INS and breast cancer: Among these, ML-RO-0 was further selected as it provided a major relative importance to the group of features linked to glucose metabolism (Group 5) (Table 2), which is currently considered an important contributor to BC progression [18,19], at the point that metformin—an anti-diabetic drug with insulin-lowering effects—has been proposed in combination with chemotherapy [20,21] and is currently being considered vs. placebo in a phase-III randomized trial in early stage BC (ClinicalTrials.gov Identifier: NCT01101438).